At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
MLYS Mineralys Therapeutics, Inc.
Not Yet Opened 11-04 16:00:00 EST
13.50
+0.05
+0.37%
盘后13.50
+0.000.00%
17:48 EST
High13.75
Low13.41
Vol95.62K
Open13.48
D1 Closing13.45
Amplitude2.53%
Mkt Cap671.31M
Tradable Cap321.79M
Total Shares49.73M
T/O1.29M
T/O Rate0.40%
Tradable Shares23.84M
P/B--
ROE--
EPS0.00
52wk High--
52wk Low--
P/E--
Dividend--
Div.Yield--
ROA--
Mineralys Therapeutics to Announce Third Quarter 2024 Financial Results and Host Conference Call on Monday, November 11, 2024
BRIEF-Mineralys Therapeutics Completes Enrollment Ahead Of Schedule In Launch-HTN, The Second Pivotal Trial Of Lorundrostat For The Treatment Of Hypertension
Mineralys Therapeutics Completes Enrollment Ahead of Schedule in Launch-Htn, the Second Pivotal Trial of Lorundrostat for the Treatment of Hypertension
Mineralys Therapeutics, Inc., a clinical-stage biopharmaceutical company that develops therapies for the treatment of hypertension and associated cardiovascular diseases. It clinical-stage product candidate is lorundrostat, a proprietary, orally administered, highly selective aldosterone synthase inhibitor for the treatment of patients with uncontrolled or resistant hypertension. The company was incorporated in 2019 and is headquartered in Radnor, Pennsylvania.